Genetic insight into sick sinus syndrome

Rosa B. Thorolfsdottir†, Gardar Sveinbjornsson‡, Hildur M. Aegisdottir‡, Stefania Benonisdottir*, Lilja Stefansdottir, Erna V. Ivarsdottir, Gisli H. Halldorsson, Jon K. Sigurdsson, Christian Torp-Pedersen, Peter E. Weeks, Søren Brunak, David Westergaard, Ole B. Pedersen, Erik Sorensen, Kaspar R. Nielsen, Kristoffer S. Burgdorf, Karina Banasik, Wei Zhou, Lilja Stefansdottir, Gudmundur L. Norddahl, Anna Helgadottir, Ingileif Jonsdottir, Jon K. Sigurdsson, Christian Torp-Pedersen, Hildur M. Aegisdottir, David O. Arnar, Unnur Thorsteinsdottir, and Kari Stefansson

1 deCODE genetics/Amgen, Inc., Sturlugata 8, Reykjavik 101, Iceland; 2 Department of Clinical Research and Cardiology, Nordsjaelland Hospital, Dyrehavevej 29, Hillerød 2400, Denmark; 3 Department of Cardiology, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen 2100, Denmark; 4 Novo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3A, Copenhagen 2200, Denmark; 5 Department of Clinical Immunology, Naomi Hospital, Ringstedgade 77B, Naestved 4700, Denmark; 6 Department of Clinical Immunology, Copenhagen University Hospital, Blegdamsvej 9, Copenhagen 2100, Denmark; 7 Department of Clinical Immunology, Alborg University Hospital North, Urbangsvej 36, Aalborg 9000, Denmark; 8 Department of Thoracic and Occupational Medicine, St. Olavs Hospital, Trondheim University Hospital, Prinsesse Kristinas gate 3, Trondheim 7030, Norway; 9 Department of Computational Medicine and Bioinformatics, University of Michigan, 100 Washtenaw Avenue, Ann Arbor, MI 48109-2218, USA; 10 Department of Computing and Mathematical Sciences, California Institute of Technology, 1200 E California Blvd. MC 305-16, Pasadena, CA 91125, USA; 11 Faculty of Medicine, University of Iceland, Vatnsmyrarvegur 16, Reykjavik 101, Iceland; 12 Department of Cardiothoracic Surgery, Landspítali—The National University Hospital of Iceland, Hringbraut, Reykjavik 101, Iceland; 13 Department of Immunology, Landspítali—The National University Hospital of Iceland, Hringbraut, Reykjavik 101, Iceland; 14 Department of Internal Medicine: Cardiology, University of Michigan, 1500 East Medical Center Drive, Ann Arbor, MI 48109-5368, USA; 15 Department of Human Genetics, University of Michigan, 4909 Buhl Building, 1241 E. Catherine St., Ann Arbor, MI 48109-5618, USA; 16 K.G. Jebsen Center for Genetic Epidemiology, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Erling Sjølsgards gate 1, Trondheim 7491, Norway; 17 Department of Public Health and Nursing, Faculty of Medicine and Health Sciences, Norwegian University of Science and Technology, Postboks 8050, Trondheim 7491, Norway; 18 HUNT Research Centre, Department of Public Health and General Practice, Norwegian University of Science and Technology, Forskningsveien 2, Levanger 7600, Norway; 19 Statens Serum Institut, Arne Tschirnhausvej 5, Copenhagen 2300, Denmark; 20 School of Engineering and Natural Sciences, University of Iceland, Hjarðarggi 4, Reykjavik 107, Iceland

Received 28 April 2020; revised 24 August 2020; editorial decision 21 December 2020; accepted 5 January 2021; online publish-ahead-of-print 13 February 2021

See page 1972 for the editorial comment on this article (doi: 10.1093/eurheartj/ehaa1108)

Aims
The aim of this study was to use human genetics to investigate the pathogenesis of sick sinus syndrome (SSS) and the role of risk factors in its development.

Methods and results
We performed a genome-wide association study of 6469 SSS cases and 1 000 187 controls from deCODE genetics, the Copenhagen Hospital Biobank, UK Biobank, and the HUNT study. Variants at six loci associated with SSS, a reported mis-sense variant in MYH6, known atrial fibrillation (AF)/electrocardiogram variants at PITX2, ZFHX3, TTN/CCDC141, and...
SCN10A and a low-frequency (MAF = 1.1–1.8%) missense variant, p.Gly62Cys in KRT8 encoding the intermediate filament protein keratin 8. A full genotypic model best described the p.Gly62Cys association \( (P = 1.6 \times 10^{-20}) \), with an odds ratio (OR) of 1.44 for heterozygotes and a disproportionately large OR of 13.99 for homozygotes. All the SSS variants increased the risk of pacemaker implantation. Their association with AF varied and p.Gly62Cys was the only variant not associating with any other arrhythmia or cardiovascular disease. We tested 17 exposure phenotypes in polygenic score (PGS) and Mendelian randomization analyses. Only two associated with the risk of SSS in Mendelian randomization, AF, and lower heart rate, suggesting causality. Powerful PGS analyses provided convincing evidence against causal associations for body mass index, cholesterol, triglycerides, and type 2 diabetes \( (P > 0.05) \).

**Conclusion**

We report the associations of variants at six loci with SSS, including a missense variant in KRT8 that confers high risk in homozygotes and points to a mechanism specific to SSS development. Mendelian randomization supports a causal role for AF in the development of SSS.

**Graphical Abstract**

Summary of genetic insight into the pathogenesis of SSS and the role of risk factors in its development. Variants at six loci (named by corresponding gene names) were identified through GWAS and their unique phenotypic associations provide insight into distinct pathways underlying SSS. Investigation of the role of risk factors in SSS development supported a causal role for AF and heart rate and provided convincing evidence against causality for BMI, cholesterol (HDL and non-HDL), triglycerides and T2D. Mendelian randomization did not support causality for CAD, ischaemic stroke, heart failure, PR interval or QRS duration (not shown in figure). Red and blue arrows represent positive and negative associations, respectively.

**Keywords**

Sick sinus syndrome • GWAS • KRT8 • Mendelian randomization • Atrial fibrillation

**Introduction**

Sick sinus syndrome (SSS) is a complex cardiac arrhythmia and the leading indication for permanent pacemaker implantation worldwide. It is characterized by pathological sinus bradycardia, sinoatrial block, or alternating atrial brady- and tachyarrhythmias. Symptoms include fatigue, reduced exercise capacity, and syncope. Few studies have been conducted on the basic mechanisms of SSS and therapeutic limitations reflect an incomplete understanding of the pathophysiology. No specific treatment option is aimed at underlying pathways.
Genetic insight into SSS

and trying to determine who benefits from cardiac pacing can be challenging. A better understanding of mechanisms leading to SSS is crucial for improvements in treatment and prevention and genetic studies provide an opportunity to gain such insight.

Coding variants in several genes, including HCN4, SCN5A, and GNB2, have been implicated in rare familial SSS through linkage analysis and candidate gene methods. In the only published genome-wide association study (GWAS) of SSS to date, we identified a strong association with a missense variant in MYH6, encoding the alpha-heavy chain subunit of cardiac myosin. This was the first GWAS discovery implicating a cardiac structural or contractile unit as a primary cause of arrhythmia.

Age is the strongest risk factor for SSS, potentially reflecting degenerative fibrosis and electrical remodelling of the SA node and the atria in general. SSS often coexists with the more common atrial fibrillation (AF) and the two arrhythmias are thought to predispose to each other. We have previously examined the role of AF in SSS development through Mendelian randomization, a method using sequence variants associated with a risk factor (AF) as unbiased proxy indicators to determine whether the risk factor can cause a disease (SSS). The study supported causality, likely mediated through atrial remodelling. Several other traits have been associated with SSS while the nature of the associations has not been ascertained. These include body mass index (BMI), height, heart rate, and cardiovascular diseases such as hypertension, myocardial infarction, heart failure, and stroke.

To gain insight into the pathogenesis of SSS, we performed a large GWAS of over 6000 cases and one million controls of European descent. We used polygenic scores (PGSs) and Mendelian randomization to determine the nature of the associations of risk factors with SSS and in particular whether they contribute to the cause of the disease.

Methods

The study design is two-fold (Supplementary material online, Figure S1). First, we performed a meta-analysis of GWASs, searching for associations of sequence variants with SSS. In total 6469 SSS cases were compared to 1 000 187 controls in a meta-analysis of material from deCODE genetics Iceland, the Copenhagen Hospital Biobank Cardiovascular Study (CHB-CVS)/Danish Blood Donor Study (DBDS), and the UK Biobank, with follow-up in the Norwegian Nord-Tøndelag Health Study (HUNT). Second, we performed PGS analysis and Mendelian randomization to examine the role of putative risk factors in SSS development (for detailed methods, see Supplementary material online).

Sick sinus syndrome study populations

The deCODE genetics SSS sample consisted of 3577 Icelanders diagnosed with SSS and 347 764 controls. The CHB-CVS included 2209 SSS cases. The control group included blood donors from the DBDS (N > 99 000) and SSS cases were also compared to subjects in CHB-CVS with other cardiovascular conditions (N > 89 000). The SSS population from the UK Biobank consisted of 403 cases and 403 181 controls. The HUNT cohort consisted of 280 Norwegian SSS cases and 69 141 controls recruited through a population-based health survey conducted in the Nord-Tøndelag County, Norway. In all four cohorts, SSS diagnosis was based on International Classification of Diseases 9th (ICD-9: 427.8) or 10th revision (ICD-10: H49.5) from hospitals and/or outpatient clinics. The cohorts are described in more detail in Supplementary material online, Methods and Supplementary material online, Table S1.

Genotyping

The deCODE study was based on whole-genome sequence data from 28 075 Icelanders participating in various disease projects. The 32.9 million variants that passed quality threshold were imputed into 127 175 Icelanders who had been genotyped using Illumina SNP chips. Finally, genotype probabilities for untyped relatives were calculated based on Icelandic genealogy. Genotyping for CHB-CVS and DBDS was performed at deCODE using a north European sequencing panel of 15 576 individuals (including 8429 Danes) for imputation into those chip typed (methods manuscript in preparation). Genotyping in the UK Biobank has been described in detail elsewhere. Illuma HumanCoreExome arrays were used for genotyping in the HUNT cohort.

Genome-wide association study: statistical analysis

We performed a meta-analysis of GWAS of 6189 SSS cases and 931 046 controls from deCODE genetics, CHB-CVS/DBDS, and the UK Biobank. We then tested genome-wide significant and suggestive variants (Supplementary material online, Methods) among 280 cases and 69 141 controls from the Norwegian HUNT study. We used logistic regression to test for association between sequence variants and SSS and other case-control phenotypes, treating phenotype status as the response and allele count as a covariate. Other available individual characteristics that correlate with phenotype status were included in the model as nuisance variables. SSS associations were tested under additive, recessive, and full genotypic models. The full genotypic model includes separate parameters for heterozygotes and homozygotes. We corrected the threshold for genome-wide significance for multiple testing with a weighted Bonferroni adjustment using as weights the enrichment of variant classes with predicted functional impact among association signals estimated from the Icelandic data. Significance thresholds were 1.3 × 10^{-7} for variants with high impact, 2.6 × 10^{-8} for variants with moderate impact (including missense), 2.4 × 10^{-9} for low-impact variants, 1.2 × 10^{-9} for other variants in Dnase I hypersensitivity sites, and 7.5 × 10^{-10} for all other variants. We used linear regression to test variant associations with quantitative phenotypes, treating the quantitative measurement as response and the genotype as covariate. These included endophenotypes of SSS, chronotropic response to exercise (N = 7746), and electrocardiogram (ECG) measurements (N ~ 73 000) (see Supplementary material online, Methods for detail).

Analysis of genetic risk shared by sick sinus syndrome and putative risk factors

We used PGSs for 17 exposure phenotypes to examine their correlation with SSS (Supplementary material online, Table S2). The phenotypes were chosen because of reported epidemiological associations with SSS or other cardiovascular conditions (see Supplementary material online, Methods). The PGSs were generated using summary statistics from the largest available GWASs (training sample) for each phenotype that do not include deCODE data (Supplementary material online, Table S2 and Supplementary material online, Figure S1). Subsequently, they were tested for association with the risk of SSS among 2556 chip-typed individuals from deCODE (target sample). P-values were corrected using genomic control.

The use of PGSs to detect association between exposure and outcome is a robust method such that the absence of association in a well-powered PGS analysis provides strong evidence against causality. However, finding association in PGS analysis does not confirm causality. For the eight PGSs that associated with SSS, we performed a 2-sample Mendelian randomization analysis, equivalent to a fixed effect
Table 1

| Locus | Effect allele/other | Variant annotation | Coding change | Closest gene | OR (95% CI) |
|-------|---------------------|---------------------|---------------|--------------|-------------|
|       |                     | EAFa (%)            |               |              | P-value     |
|       |                     |                     |               |              |             |
| 1     | A/G                 | 2.6                  | Missense      | MYH6         | 10-70       |
|       |                     | 8.88                 | p.Arg721Trp   |              | 10-15       |
| 2     | C/T                 | 20.07                | Intronic      | MIR297, PITX2| 10-15       |
|       |                     | 1.62                 |               |              | 9.4-10-10   |
| 3     | A/G                 | 1.64                 | Missense      | KRT8         | 10-14       |
|       |                     | 1.62                 | p.Gly62Cys    |              | 10-10       |
| 4     | T/G                 | 26.63                | Missense      | ZFHX3        | 10-14       |
|       |                     |                      | p.Thr811ile   |              | 10-9        |
| 5     | A/G                 | 15.58                | Missense      | TTN          | 10-14       |
|       |                     |                      | p.Glu382Asp   |              | 10-9        |
| 6     | A/G                 | 35.78                | Missense      | SCN10A       | 10-14       |

**Results**

**Six sick sinus syndrome loci**

In a GWAS comparing 6469 SSS cases to 1 000 187 controls, variants at six loci satisfied our criteria for genome-wide significance (Table 1, Supplementary material online, Table S3, Figure 1, and Supplementary material online, Figure S2), with ORs ranging from 1.12 to 8.88. One is at a novel SSS locus, a low-frequency missense variant, p.Gly62Cys (MAF = 1.1–1.8% in the four cohorts) in the gene MYH6 on chromosome 12. This variant has not been associated with arrhythmias or ECG traits before. The other variants are the rare Icelandic SSS missense variant p.Arg721Trp in the sarcomere gene MYH6,16 common variants at two AF loci, PITX220 and ZFHX3,31 and two ECG loci, TTN/CCDC14152 and SCN10A.52–54 We have previously reported secondary associations of variants at the four AF and ECG loci with SSS.21,52 At the TTN/CCDC141 locus, we report associations of two missense variants, p.Thr811ile in TTN and p.Glu382Asp in CCDC141, that are weakly correlated (R² = 0.20, D’ = 0.64, Supplementary material online, Table S4).

**High penetrance of sick sinus syndrome among homozygotes for p.Gly62Cys in KRT8**

The SSS association of p.Gly62Cys in KRT8 was discovered with the additive model (Table 1 and Supplementary material online, Tables S5 and S6). However, homozygotes of p.Gly62Cys have a higher risk of SSS than assumed under the additive model (Table 2, homozygous genotypic OR > 1.62² = 2.62, Pfull vs. additive = 2.1 × 10⁻⁸). We observed an OR of 1.44 for heterozygotes (95% CI = 1.26–1.65) and 13.99 for homozygotes (95% CI = 8.16–23.98), compared to non-carriers (P-value for the full genotypic model = 1.6 × 10⁻²⁰, Table 2). None of the other SSS associations deviated from the additive model (P > 0.05). KRT8 encodes the intermediate filament keratin 8 (K8, Supplementary material online, Figure S3) which is widely expressed, including in the heart,36 and we detected its expression (52.1 ± 30.2 transcripts per million) in our cardiac samples from right atria (n = 169, Supplementary material online, Methods). Neither p.Gly62Cys nor two correlated variants (R² > 0.6) associated with the expression of KRT8 or nearby genes (1 Mb) in our cardiac samples (Supplementary material online, Table S7) or in GTEx.35

About 1 in 5000 individuals from the four European populations in this study is homozygous for p.Gly62Cys in KRT8, consistent with the MR-Egger using published genome-wide significant SNPs from the largest available GWAS on each exposure phenotype as genetic instruments.31–49 To estimate the causal effect, we regressed the published effects of the SNPs on the respective exposure phenotype against their SSS effects in deCODE, CHB-CVS/DBDS, and the UK Biobank, using minor allele frequency (MAF) × (1 - MAF) as weights. For the ECG measurements PR interval and QRS duration, effects in milliseconds were converted to standard deviations (SDs) according to one SD in the Icelandic data so that all causal estimates in a Mendelian randomization forest plot correspond to equal odds ratio (OR) or SD changes for binary and quantitative traits, respectively. For significant associations, we performed further sensitivity analysis to detect outliers (funnel plots) and tested for directional pleiotropy using the MR-Egger intercept test (see Supplementary Material online, Methods).40
Hardy–Weinberg equilibrium ($P = 0.071–0.82$). To evaluate the penetrance of SSS among homozygous carriers of p.Gly62Cys, we analysed the two largest SSS datasets in the study, deCODE and CHB-CVS/DBDS. Considering that SSS is a late onset disease, the observed penetrance is relatively high although incomplete (Figure 2). Eight out of 36 genotyped Icelandic homozygotes (aged 23–88 years, mean 59.9) had SSS (Supplementary material online, Table S8) and 10 out of 79 homozygotes (aged 27–103 years, mean 62.1) in CHB-CVS/DBDS. Homozygotes were not significantly younger at SSS diagnosis than heterozygotes or non-carriers ($P = 0.53$ in deCODE and $P = 0.26$ in CHB-CVS/DBDS, Supplementary material online, Table S9).

Diverse associations of sick sinus syndrome variants with other phenotypes

We tested the associations of the SSS variants with other phenotypes in deCODE, CHB-CVS/DBDS, and the UK Biobank datasets (Supplementary material online, Tables S10–S14). In addition to SSS, p.Gly62Cys in KRT8 associated with pacemaker implantation (OR heterozygotes = 1.28, 95% CI = 1.13–1.45, OR homozygotes = 9.17, 95% CI = 2.89–29.09, $P = 1.9 \times 10^{-6}$). The variant did not associate with other arrhythmias or cardiovascular diseases, with electrolyte or hormonal disturbances that are linked to the development of SSS (potassium, calcium, thyroid stimulating hormone) or with the suggested consequence of p.Gly62Cys in candidate gene studies (pancreatitis/lipase, liver disease, Bonferroni-adjusted significance threshold of $P = 0.05/23 = 0.0022$, Supplementary material online, Tables S10 and S11). Furthermore, p.Gly62Cys did not associate with any of the 122 ECG parameters ($N$ up to 72,825, Supplementary material online, Table S13).

The associations of SSS variants with AF varied. p.Gly62Cys in KRT8 (Supplementary material online, Tables S10 and S11) and the missense variants in TTN/CCDC141 (Supplementary material online, Table S12) did not associate with the risk of AF, applying a Bonferroni-corrected significance threshold of $P < 0.05/14 = 0.0036$. The TTN/CCDC141 variants are located within 300 kbp from previously reported AF variants and are independent of them ($R^2 < 0.2$, Supplementary material online, Figure S4). The other four SSS loci have been reported to affect AF but their pattern of association with the two phenotypes differ. p.Arg721Trp in MYH6 associates stronger with SSS than AF but the reverse applies to variants at PITX2. At ZFHX3, the effects on AF and SSS are comparable. p.Val1073Ala in SCN10A is one of the top AF variants at this locus (Supplementary material online, Figure S5), but the allele that...
increases the risk of SSS protects against AF (Supplementary material online, Table S12).53,61

All the SSS variants increased the risk of pacemaker implantation (Supplementary material online, Tables S10–S12), as expected since SSS is the most common reason for this procedure. We have previously described in detail the associations of p.Arg721Trp in MYH6 with coarctation of the aorta, other congenital malformations of the heart, aortic valve stenosis, and heart failure23,62,63 (Supplementary material online, Table S12). We note that p.Glu382Asp in CCDC141 associated with both second- and third-degree atrioventricular block (AVB)62 and the association with third-degree AVB was genome-wide significant (P = 1.3 × 10^{-14}, OR = 1.27, 95% CI = 1.20–1.35) and more significant than the SSS association. Another notable association is that of the PITX2 variant with heart failure (Supplementary material online, Table S12) as recently reported in a GWAS of heart failure.47 None of the SSS variants associated with chronotropic response to exercise (Supplementary material online, Tables S15 and S16) in our dataset. However, the SCN10A and CCDC141 loci have been reported to associate with heart rate profile during exercise in larger studies of UK Biobank data.64,65

### Genetically predicted atrial fibrillation and lower heart rate associate with sick sinus syndrome

PGSs are powerful tools for detecting associations between phenotypes.38 We generated PGSs for 17 exposure phenotypes using summary statistics from the largest available GWASs (Supplementary material online, Table S2) and tested them for association with SSS in deCODE data. Eight PGSs, for AF, heart rate, coronary artery disease (CAD), height, QRS duration, PR interval, ischaemic stroke, and heart failure, associated with SSS while those for BMI, type 2 diabetes (T2D), non-HDL cholesterol, HDL cholesterol, triglycerides, and hypertension/blood pressure traits did not (Bonferroni-adjusted significance threshold of P = 0.05/17 = 0.0029, Supplementary material online, Table S17). The PGS for heart rate was the only one to inversely associate with SSS risk.

We then performed Mendelian randomization to determine the causality of the associations between the eight exposures and SSS, using genome-wide significant SNPs from GWAS of the exposure phenotypes as instruments (see Methods). Genetic predisposition to AF and genetically determined heart rate and height associated with the risk of SSS but the height association did not remain after accounting for AF in a multivariate analysis (Figures 3 and 4A and B).66–68 With few exceptions, the effects of AF variants on SSS are proportional to their effects on AF (P = 7.8 × 10^{-14}, Figure 4A and Supplementary material online, Figure S6A). The greatest deviation from the expected SSS effect was for the association at SCN10A (tagged by rs6790693, OR for AF = 1.06, OR for SSS = 0.89, Supplementary material online, Figure S6A). Mendelian randomization did not support causality for CAD, ischaemic stroke, heart failure, PR interval, or QRS duration (Figure 3 and Supplementary material online, Figure S7).

| Renname/Pos (hg19) | Effect allele/other | Coding change | EAF (%) | Risk for heterozygous carriers, OR (95% CI) | Risk for homozygotes, OR (95% CI) | P-value for full genotypic model |
|------------------|------------------|---------------|---------|--------------------------------------|----------------------------------|---------------------------------|
| rs11554495/chr12:52904798 A/C | p.Gly62Cys | deCODE 3577 1.64 1.42 (1.17–1.72) 12.95 (4.58–36.63) 1.5 × 10^{-9} | CHB-CVS 2209 1.77 1.34 (1.08–1.66) 16.13 (6.24–41.67) 10^{-10} | UK Biobank 403 1.05 2.35 (1.42–3.88) 17.90 (0.74–435.16) 0.00012 | Combined 6469 – 1.44 (1.26–1.65) 13.99 (8.16–23.98) 1.6 × 10^{-20} |
Discussion

Traditionally, SSS has been considered as a collection of conditions with a variety of causes, intrinsic and extrinsic to the SA node.69 In line with this notion, we identified sequence variants associating with SSS at six loci implicating several distinct pathways in SSS development. One of the SSS associations is novel, with a low-frequency missense variant, p.Gly62Cys in KRT8. One is with the reported p.Arg721Trp in MYH6,16 and four confirm loci previously implicated in SSS secondarily to AF, at PITX2,50 and ZFHX3,51 or ECG traits, at SCN10A53 and TTN/CCDC141.52 The leading variants at four of the SSS loci are missense.

KRT8 encodes K8, a cytoskeletal intermediate filament protein widely expressed, including in skeletal muscle and the heart.55 Historically, keratins have been described as epithelial-specific intermediate filaments70 and mutations affecting keratin function have almost exclusively been associated with diseases of the skin and other epithelial tissues.71,72 The association of p.Gly62Cys in KRT8 with SSS described here supports the notion of a role for K8 in the human heart, as previously suggested by animal studies.73–76 Experiments have revealed loss-of-function effects of p.Gly62Cys in KRT8 with SSS described here supports the notion of a role for K8 in the human heart, as previously suggested by animal studies.73–76 Experiments have revealed loss-of-function effects of p.Gly62Cys in KRT8, that is located in the head domain of K8 (Supplementary material online, Figure S3).75,76 Glycine at position 62 is a conserved amino acid (GERP score 1.73) and the variant introduces cysteine into a protein otherwise devoid of cysteine residues. This interrupts intermediate filament assembly in vitro77 and prevents K8 from serving as a phosphate ‘sponge’ for stress-activated kinases that mediate apoptosis.78 Thus, the variant could increase the risk of SSS either by affecting the structural or cardioprotective role of K8.77,78

In addition to p.Gly62Cys in KRT8, lead variants at two other SSS loci are missense variants in genes encoding structural components of the heart. MYH6 encodes the alpha-myosin heavy chain (αMHC) and TTN encodes the giant protein titin, both of which are key components of the sarcomere.80,81 Since the identification of MYH6 in
the first GWAS of SSS, structural components of cardiomyocytes have increasingly been implicated in atrioventricular conduction and arrhythmias, in particular AF. However, the variants at KRT8, MYH6 and TTN do not mediate their risk through AF because they either do not associate with AF (KRT8 and TTN) or have a stronger effect on SSS risk (MYH6).

K8, αMHC, and titin have a common role in cardiac adaptive responses to stress which may be of relevance to their association with SSS. αMHC allows greater economy in force generation than the homologous β chain and a shift in their relative expression plays a major role in regulating myocardial contractile activity. Likewise, the isoform switch of titin alters ventricular filling and K8 is upregulated under stress to maintain structural integrity. The expression of all three genes is modified in human heart failure. Thus, whether or not the SSS variants in KRT8, MYH6 and TTN directly affect the SA node, it is possible that they could contribute to inadequate cardiac output and symptom development in SSS by interrupting adaptive increase in stroke volume.

The SSS variants at PITX2 and ZFHX3 point to genes encoding transcription factors. They likely mediate their effects on SSS through AF since these have consistently been the strongest AF loci in GWAS. Conversely, p.Val1073Ala in SCN10A has opposite effects on the two arrhythmias. The allele that increases the risk of SSS protects against AF. The PR interval and duration of the QRS complex. SCN10A encodes the neuronal sodium channel isoform Na1.8. A plausible mechanism behind the unique phenotypic effects of p.Val1073Ala involves Na1.8s role in the way in which the autonomic nervous system affects the heart. Importantly, our results also show that SSS does not only occur as a consequence of AF or pathways common to AF. This is evident in the case of SSS variants at KRT8 and TTN/CCDC141 that do not associate with the risk of AF in a large dataset. p.Gly62Cys in KRT8 is the only SSS variant that does not associate with other arrhythmias, ECG traits, or cardiovascular diseases in our dataset. Thus, this variant in particular may point to a mechanism that is specific to SSS development. We observe a genome-wide significant association of p.Glu382Asp in CCDC141 with third-degree AVB, the first one reported for complete heart block. Therefore, this locus points to a...
mechanism linking the functions of the AV and SA nodes and does not mediate the risk of SSS as a consequence of AF. The complexity of the relationship between SSS and AF is further evident by the opposite effects of the SCN10A locus on the two arrhythmias. Finally, since SSS variants do not consistently associate with AF, our data do not suggest a strong causal role for SSS in the development of AF.

Heart rate variants associate inversely with SSS, consistent with epidemiological observation, potentially because bradycardia is an integral part of the SSS diagnosis. However, lower heart rate could also represent a direct marker of biological processes affecting SSS, such as fibrosis or altered autonomic neural input. Finally, lack of associations with powerful PGSs based on large datasets serves as convincing evidence against causality. In particular, this applies to BMI, cholesterol, triglycerides, and T2D.

Several of our findings have direct clinical implications. In particular, the causal role of AF in SSS development emphasizes the need for heightened awareness of potential SSS among patients with AF, especially those with unspecific symptoms. Furthermore, the strong association of the SSS variant p.Glu382Asp in CCDC141 with AVB encourages consideration of dual chamber pacemaker implantation in SSS patients carrying this variant. Lastly, the SCN10A locus points to SSS as a potential adverse effect of GP ablation therapy for AF.

The major strength of the study is the large SSS sample set and extensive phenotypic and genotypic data for the same datasets. Different proportions of comorbidities and drug use in SSS cases and controls could constitute confounding; however, the consistent associations of SSS variants with both SSS and pacemaker implantation across cohorts support their true effect on cardiac conduction. Furthermore, if a specific comorbidity would explain one of the SSS associations, this would be evident by a stronger effect on that phenotype. The strength of Mendelian randomization in determining causality includes less concern for confounding and reverse causation than in observational studies since sequence variants associated with the exposure (e.g. AF) are randomized during meiosis and this process is unaffected by the presence of the outcome (SSS) later in life. For heart failure, a limitation of the Mendelian randomization approach is that variants identified in GWAS are not ideal instruments because of their association with potential confounders (e.g. AF, CAD, and BMI).

Conclusion

In this large genetic study, we found six SSS loci, some of which also associate with other arrhythmias and cardiac electrical function. One of the associations is with a missense variant in the intermediate filament gene KRT8 that confers high risk of SSS among homozygous carriers. Mendelian randomization analysis suggests that AF and lower heart rate are directly involved in SSS development. PGS analysis provides convincing evidence against causality for BMI, cholesterol, triglycerides, and T2D. On the other hand, the data also show that SSS can result from perturbation of pathways unrelated to AF. In particular, p.Gly62Cys at KRT8 does not associate with any other cardiovascular traits and points to a mechanism that is specific to SSS development.

Supplementary material

Supplementary material is available at European Heart Journal online.

Data availability

The Icelandic population WGS data has been deposited at the European Variant Archive under accession code PRJEB15197. We declare that the data supporting the findings of this study are available within the article, its Supplementary material online and upon reasonable request. The genome-wide association scan summary data will be made available at http://www.decode.com/summarydata.

Acknowledgements

We thank all the study subjects for their valuable participation as well as our colleagues that contributed to data collection, sample handling, and genotyping.

Funding

This work was partly supported by NordForsk through the funding to PM Heart, project number 90580, the Innovation Fund Denmark (IFD) under File No. 8114-00033B and the Technology Development Fund, Iceland, project number 90580.

Conflict of interest: The following authors affiliated with deCODE genetics/Amgen, Inc., are employed by the company: R.B.T., G.S., H.M.A., S.B., L.S., E.V.I., G.H.H., J.K.S., A.O., V.T., K.E.H., O.B.D., S.R., S.J., G.T., M.L.F., G.T., G.L.N., A.H., S.G., P.S., I.J., D.O.A., U.T., D.F.G., H.H., and K.S.. D.W. received grants from Novo Nordisk Foundation during the conduct of the study. S.B. is a board member for Proscion A/S and Intomics A/S.

References

1. Mond HG, Proclemer A. The 11th world meeting of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009—a World Society of Arrhythmia’s project. Pacing Clin Electrophysiol 2011;34:1013–1027.
2. Ferrer M. The sick sinus syndrome. Circulation 1973;47:635–641.
3. Fuster V, Harrington RA, Narula J, Espen ZJ, Hurst’s the Heart. 14th ed. New York: McGraw-Hill Education; 2017.
4. Brignole M, Auricchio A, Baron-Esquivias G, Bordachar P, Boriani G, Breithardt OA, Cieland J, Deharo JC, Delgado V, Eliott PM, Gorenhek B, Israel CW, Lelecreq C, Linde C, Mont L, Padeletti L, Sutton R, Vardas P. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013;15:1070–1118.
5. Le Scouarnec S, Bhasin N, Veyres C, Hund Tj, Cunha SR, Koval O, Marquonneau C, Chen B, Wu Y, Demolombe S, Song LS, Le Marec H, Probst V, Schott Jj, Anderson ME, Mohler Pf. Dysfunction in ankyrin-B dependent ion channel and transporter targeting causes human sinus node disease. Proc Natl Acad Sci USA 2008;105:15617–15622.
6. Zhu YB, Luo JW, Jiang F, Liu G. Genetic analysis of sick sinus syndrome in a family harboring compound CACNA1C and TTN mutations. Mol Med Rep 2018;17:7073–7080.
7. Bensan DW, Wang DW, Dyment M, Knillas TK, Fish FA, Strieper MJ, Rhodes TH, George AL Jr. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 2003;112:1019–1028.
8. Makita N, Sasaki K, Groenewegen WA, Yokota T, Yokoshiki H, Murakami T, Tsutsumi H. Congenital atrial standstill associated with concurrence of a novel SCN5A mutation and connexin 43 polymorphisms. Heart Rhythm 2005;2:1126–1134.
9. Makioyama T, Akao M, Tsuji K, Doh T, Ohno S, Takenaka K, Kobori A, Ninomiya T, Yoshida H, Takano M, Makita N, Yanagisawa F, Higashi Y, Takeyama Y, Kita T, Horie M. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol 2005;46:2100–2106.
10. Ishikawa T, Ohno S, Murakami T, Yoshida K, Mihama H, Fukuda T, Kimoto H, Sakamoto R, Ohkusa T, Aiba T, Nagami A, Sumitomo N, Shimizu W, Yoshiiro KI, Horigome H, Horie M, Makita N. Sick sinus syndrome with HCN4 mutations.
Genetic insight into SSS

43. Guo Y, Chung W, Zhu Z, Shan Z, Li J, Liu S, Liang L. Genome-wide assessment

44. Yengo L, Sidorenko J, Kemper KE, Zheng Z, Wood AR, Weedon MN, Frayling

45. van der Harst P, Verweij N. Identification of 64 novel genetic loci provides an

37. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ,

2018;

Nat Genet

Eur J Epidemiol

PT. Multi-ethnic genome-wide association study for atrial fibrillation.

2020;

Nat Commun

randomisation analysis provide insights into the pathogenesis of heart failure.

Nat Commun 2020;11:163–163.

47. Shah S, Henry A, Roselli C, Lin H, Sveinbjörnsson G, Fatemifar G, Hedman ÅK,

50.4524–537.

50.5042–523.

1969

189

180

166

150

130

120

100

80

60

40

20

0

Genetic insight into SSS

1969

37. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ,

37. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ,

37. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ,

37. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ,

37. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ,

37. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ,

37. Bulik-Sullivan BK, Loh PR, Finucane HK, Ripke S, Yang J, Patterson N, Daly MJ,
Levy D, Gudnason V, Ellinor PT, Sanna S, Ka¨a¨b S, Witteman JCM, Alonso A, WHL, Ko¨ttgen A, Coresh J, Bis JC, Psaty BM, Rice K, Rotter JI, Rivadeneira F, Gudbjartsson DF, Stefansson K. Sequence variants with large effects on cardiac conduction. Nat Commun 2020;11:2542.

Nielsen JB, Frishte LG, Zhou W, Teslovich TM, Holmen OL, Gustafsson S, Gabrielson ME, Schmidt EM, Beaurmont R, Wolfond BN, Lin M, Brummettm CR, Preuss MH, Refsgaard L, Bottinger EP, Graham SE, Surikata I, Chu Y, Skoghalt AH, Dahan H, Boyle AP, Oral H, Herrn TK, Kitzman J, Kalife J, Sveinb J, Olesen M, Madsen L, Lichtenstein A, He C, Daima BA, Baras A, Gottseman O, Marzetta A, O'Dushlaine C, Ritchie MD, Wilsgaard T, Loos RJF, Frayling TM, Boehmke K, Ingelsson E, Carey DJ, Dewey KF, Kang HM, Abecasis G, Kvin K, Wilder J. Genome-wide study of atrial fibrillation identifies seven risk loci and highlights biological pathways and regulatory elements involved in cardiac development. Am J Hum Genet 2018;102:103–115.

Ritchie MD, Denny JC, Zwizh RL, Crawford DC, Schildorlj JS, Bastarche L, Ramire Az K, Mosley JD, Pulley J, Danford MA, Bradford Y, Rasmussen LR, Pathak J, Chute CG, McCarty CA, Chisholm RL, Kho AN, Haines JL, Roden DM. Genome- and phenotype-wide analyses of cardiac conduction identities markers of arrhythmia risk. Circulation 2013;127:1377–1385.

Thorleifsson G, Stefansson K. Variants conferring risk of atrial fibrillation on chromosome 4q25. Nat Genet 2010;42:153–159.

Thorleifsson G, Stefansson K. Variants conferring risk of atrial fibrillation on chromosome 4q25.

Thorleifsson G, Stefansson K. Variants conferring risk of atrial fibrillation on chromosome 4q25.
Genetic insight into SSS

1971

71. Coulombe PA, Ormey MB. ‘Hard’ and ‘soft’ principles defining the structure, function and regulation of keratin intermediate filaments. Curr Opin Cell Biol 2002;14:110–122.

72. Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochern Cell Biol 2008;129:705–733.

73. O'Neill A, Williams MV, Resnek WG, Milner DJ, Capetanaki Y, Bloch RJ. Sarcolemmal organization in skeletal muscle: evidence for cytoskeletal keratins associated with the membrane skeleton at costameres. Mol Biol Cell 2002;13:2347–2359.

74. Uristi JA, Lee PC, Resnek WG, McNally MM, Bowman AL, O'Neill A, Stone MR, Bloch RJ. Cloning and characterization of cytoskeletal 8 and 19 in adult rat striated muscle. Interaction with the dystrophin glycoprotein complex. J Biol Chem 2005;280:41830–41838.

75. Stone MR, O'Neill A, Catino D, Bloch RJ. Specific interaction of the actin-binding domain of dystrophin with intermediate fila-ments containing keratin 19. Mol Biol Cell 2005;16:4280–4293.

76. Papathanasiou S, Rickelt S, Soriano ME, Schips TG, Maier HJ, Davos CH, Varela A, Kalamani M, Mann DL, Capetanaki Y. Tumor necrosis factor-alpha confers cardioprotection through ectopic expression of keratins KB and K18. Nat Med 2015;21:1076–1084.

77. Ouwens DW, Wilson NJ, Hill AJ, Rugg EL, Porter RM, Hutcheson AM, Quinlan 76. Papathanasiou S, Rickelt S, Soriano ME, Schips TG, Maier HJ, Davos CH, Varela A, Kalamani M, Mann DL, Capetanaki Y. Tumor necrosis factor-alpha confers cardioprotection through ectopic expression of keratins KB and K18. Nat Med 2015;21:1076–1084.

78. Ku NO, Omary MB. A disease- and phosphorylation-related nonmechanical function for keratin 8. J Cell Biol 2006;174:115–125.

79. Cooper GM, Stone EA, Asimenos G, Green ED, Batzoglou S, Sidow A.

80. England J, Loughna S. Heavy and light roles: myosin in the morphogenesis of the striated muscle. Interaction with the dystrophin glycoprotein complex. J Biol Chem 2005;280:41830–41838.

81. Granzier HL, Labeit S. The giant protein titin: a major player in myocardial mechanics, signaling, and disease. Circ Res 2013;112:1221–1239.

82. Gudbjartsson DF, Holm H, Sulem P, Masson G, Oldfors A, Magnusson OT, Saemundsdottir J, Helgadottir HT, Helgason H, Johannsdottir H, Gretarsdottir S, Guoqian SA, Itoh I, Lothen ML, Baer M, Ma RC, Sigfusson G, Kong A, Thorgerisson G, Sverrisson JT, Thorsteinsdottir U, Stefansson K, Arna DO. A frameshif deletion in the sarcomere gene M/Y24 causes early-onset familial atrial fibrillation. Eur Heart J 2017;38:27–34.

83. Thorolfsdottir R, Sveinbjornsson G, Sulem P, Nielsen JB, Jonsson S, O'Neill A, Williams MW, Resnek WG, McNally MM, Bowman AL, O'Neill A, Stone MR, Bloch RJ. Cloning and characterization of cytoskeletal 8 and 19 in adult rat striated muscle. Interaction with the dystrophin glycoprotein complex. J Biol Chem 2005;280:41830–41838.

84. Musaka S, Minobe W, Bristow MR, Lenswand LA. Myosin heavy chain isoform expression in the failing and nonfailing human heart. Circ Res 2000;86:386–390.

85. James J, Martin L, Krenz M, Quatman C, Jones F, Klevitsky R, Gulick J, Robbins J. Forced expression of alpha-myosin heavy chain in the rabbit ventricle results in cardioprotection under cardiomyopathic conditions. Circulation 2005;111:2339–2346.

86. Cazoria O, Freiburg A, Helmes M, Centner T, McNabb M, Wu Y, Trombitas K, Labetz S, Granzier H. Differential expression of cardiac titin isoforms and modulation of cellular stiffness. Circ Res 2000;86:59–67.

87. Nagueh SF, Shah G, Wu Y, Torre-Amione G, King NM, Lahmers S, Witt CC, Becker K, Labetz S, Granzier H. Altered titin expression, myocardial stiffness, and left ventricular function in patients with dilated cardiomyopathy. Circulation 2004;110:155–162.

88. Piedra ME, Icardo JM, Albajar M, Rodríguez-Rey JC, Ros MA. Ptx2 participates in the late phase of the pathway controlling left-right asymmetry. Cell 1998;94:319–324.

89. Berry FB, Miura Y, Mihara K, Kaspar P, Sakata N, Hashimoto-Tamaoki T, Tamaoki T. Positive and negative regulation of myogenic differentiation of C2C12 cells by isoforms of the multiple homeodomain zinc finger transcription factor ATBF1. J Biol Chem 2001;276:25057–25065.

90. Chen X, Wu L, Shi S, Jiang H, Huang C, Desai M, Li Y, Barajas-Martinez H, Hu D. Neuronal Nav1.8 channels as a novel therapeutic target of acute atrial fibrillation prevention. J Am Heart Assoc 2016;5:e00450.

91. Qi B, Wei Y, Chen S, Zhou G, Li H, Xu J, Ding Y, Lu X, Zhao L, Zhang F, Chen G, Zhao J, Liu S. Nav1.8 channels in ganglionated plexi modulate atrial fibrillation inducibility. Cardiovasc Res 2014;102:480–486.

92. Jabbari J, Olesen MS, Yuan L, Nielsen JB, Liang B, Macri V, Christophersen IE, Nielsen N, Sadjadieh A, Ellinor PT, Grunnet M, Haunso S, Holst AG, Svendsen JH, Jespersen T; on behalf of LuCamp. Common and rare variants in SCN1A modulate the risk of atrial fibrillation. Circ Cardiovasc Genet 2015;8:64–73.

93. Katritsis DG, Pokushalov E, Romanov A, Giazitzoglou E, Sions GC, Po SS, Camm AJ, Ioannidis JP. Autonomic denervation added to pulmonary vein isolation for paroxysmal atrial fibrillation: a randomized clinical trial. J Am Coll Cardiol 2013;62:2318–2325.

94. Nakagawa H, Scherlag BJ, Patterson E, Aldea A, Lockwood DJ, Jackman WM. Pathophysiological basis of autonomic ganglionated plexus ablation in patients with atrial fibrillation. Heart Rhythm 2009;6:526–34.

95. Pokushalov E, Romanov A, Katritsis DG, Artymenko S, Shirokova N, Karasov A, Mittal S, Steinberg JS. Ganglionated plexus ablation vs linear ablation in patients undergoing pulmonary vein isolation for persistent/long-standing persistent atrial fibrillation: a randomized comparison. Heart Rhythm 2013;10:1280–1286.

96. Buckley U, Rajendran PS, Shivkumar K. Ganglionated plexus ablation for atrial fibrillation: just because we can, does that mean we should? Heart Rhythm 2017;14:133–134.

97. Lo LW, Scherlag BJ, Chang HY, Lin YJ, Chen SA, Po SS. Paradigmatic long-term proarrhythmic effects after ablation of the “head station” ganglionated plexus of the vagal innervation to the heart. Heart Rhythm 2013;10:75–77.

98. Osman F, Kundu S, Tian J, Jelan M, Stafford PJ, Ng GA, Ng GA. Ganglionic plexus ablation during pulmonary vein isolation—predisposing to ventricular arrhythmia? Indian Pacing Electrophysiol J 2010;10:104–107.

99. Drissens AHG, Berger WR, Krull SPF, van den Berg NWE, Neefs J, Piersma FR, Chan Pin Yin D, de Jong J, van Boon VP, de Groot JR. Ganglion plexus ablation in advanced atrial fibrillation: the AFACT study. J Am Coll Cardiol 2016;68:1155–1165.

100. Elvan A, Wylie K, Zipes DP. Pacing-induced chronic atrial fibrillation impairs sinus node function in dogs. Electrophysiological remodeling. Circulation 1996;94:2953–2960.

101. Mesubi AO, Anderson ME. Atrial remodeling in atrial fibrillation: CaMKII as a nodal proarrhythmic signal. Cardiovasc Res 2016;109:542–557.